Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: Correlation with patient age and survival

Journal of Neurosurgery

Volumn 95, Issue 4, 2001, Pages 651-659

  Tada, K ^a   Shiraishi, S ^a   Kamiryo, T ^a   Nakamura, H ^a   Hirano, H ^a   Kuratsu, J I ^a   Kochi, M ^a   Saya, H ^a   Ushio, Y ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Age; Chromosome 10; Glioma; Loss of heterozygosity; Survival

Indexed keywords

ADOLESCENT; ADULT; AGING; ARTICLE; ASTROCYTOMA; CANCER SURVIVAL; CHROMOSOME 10; CHROMOSOME MAP; FEMALE; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; PROGNOSIS; RATING SCALE;

EID: 0034761379     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.2001.95.4.0651     Document Type: Article

References (49)

1. Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q
2. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas
3. Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas
4. Cytogenetics of human brain tumors
5. Specific chromosomal abnormalities in malignant human gliomas
6. A novel gene, LGI 1, from 10q24 is rearranged and downregulated in malignant brain tumors
7. Gene and chromosomal alterations associated with the development of human gliomas
8. Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials
9. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome
10. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter
11. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression
12. Deletion mapping of the long arm of chromosome 10 in glioblastoma multiforme
13. Allelotype of human malignant astrocytoma
14. Genetics and malignant progression of human brain tumours
15. Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers
16. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma
17. The 1993-94 Généthon human genetic linkage map
18. Clonal genomic alterations in glioma malignancy stages
19. Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach
20. Loss of heterozygosity in malignant gliomas involves at least three distinct regions on chromosome 10
21. Phenotype vs genotype in the evolution of astrocytic brain tumors
22. Structural and functional evidence for the presence of tumor suppressor genes on the short arm of chromosome 10 in human gliomas
23. Pathways leading to glioblastoma multiforme: A molecular analysis of genetic alterations in 65 astrocytic tumors
24. Allele loss on chromosomes 10 and 17p and epidermal growth factor receptor gene amplification in human malignant astrocytoma related to prognosis
25. Genetic sub-types of human malignant astrocytoma correlate with survival
26. Phase III comparison of BCNU and the combination of procarbazine. CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas
27. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer
28. Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: Relationship to prognostic significance
29. A molecular genetic model of astrocytoma histopathology
30. A tiger behind many doors: Multiple genetic pathways to malignant glioma
31. Homozygous deletion of the p16/MTS-1/CDKN2 gene in malignant gliomas is infrequent among Japanese patients
32. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours
33. Identification of a human homolog of the Drosophila neuralized gene within the 10q25.1 malignant astrocytoma deletion region
34. Loss of heterozygosity for 10q loci in human gliomas
35. Chromosome 10 deletion mapping in human gliomas: A common deletion region in 10q25
36. Effect of age and reoperation on survival in the combined modality treatment of malignant astrocytoma
37. Differential expression of MMAC/ PTEN in glioblastoma multiforme: Relationship to localization and prognosis
38. A randomized comparison of intra-arterial versus intravenous BCNU, with or without intravenous 5-fluorouracil, for newly diagnosed patients with malignant glioma
39. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001
40. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: Results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials
41. Deletion mapping of chromosome 10 in human glioma
42. Two tumor suppressive loci on chromosome 10 involved in human glioblastomas
43. Identification of a candidate tumour suppressor gene, MMAC 1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
44. Multiple sequential molecular abnormalities in the evolution of human gliomas
45. Subsets of glioblastoma multiforme defined by molecular genetic analysis
46. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery
47. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas
48. Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas